Purpose

This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) to other places in the body.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have a diagnosis of metastatic non small cell lung cancer - Undergoing 1st, 2nd or 3rd line of treatment or are in maintenance therapy - Older than 18 years old at the time of diagnosis

Exclusion Criteria

  • Subjects will be excluded if they are considered to have advanced terminal cancer, severe depression or other psychiatric disorder or a sleep disorder other than insomnia (sleep apnea, restless leg syndrome, sleep related disorder of breathing), regular use of psychotropic medication other than hypnotics (eg antidepressants) per chart review

Study Design

Phase
Study Type
Observational
Observational Model
Case-Only
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
Observational Patients undergo medical chart review and complete a questionnaire on study.
  • Other: Non-Interventional Study
    Non-interventional study

Recruiting Locations

Mayo Clinic in Rochester
Rochester 5043473, Minnesota 5037779 55905
Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu

More Details

Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Detailed Description

PRIMARY OBJECTIVE: I. Evaluate the frequency of insomnia in patients with metastatic non-small cell lung cancer. OUTLINE: This is an observational study. Patients undergo medical chart review and complete a questionnaire on study.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.